BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
March 13, 2025 17:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended...
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
March 06, 2025 17:45 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Declares First Quarter 2025 Dividend
January 30, 2025 17:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Jan. 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Announces Renewal of Normal Course Issuer Bid
December 16, 2024 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted...
BioSyent Releases Financial Results for Q3 and YTD 2024
November 20, 2024 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended...
BioSyent Declares Fourth Quarter 2024 Dividend
November 20, 2024 07:55 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
November 13, 2024 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
September 20, 2024 09:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has...
BioSyent Releases Financial Results for Q2 and H1 2024
August 26, 2024 16:45 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30,...
BioSyent Declares Third Quarter 2024 Dividend
August 26, 2024 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...